Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Rubius Therapeutics Inc
(NQ:
RUBY
)
26.62
+1.48 (+5.89%)
Streaming Delayed Price
Updated: 3:45 PM EDT, Apr 21, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Rubius Therapeutics Inc
< Previous
1
2
3
Next >
Rubius Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of RTX-321 for the Treatment of HPV 16-Positive Cancers
April 12, 2021
From
GlobeNewswire News Releases
Rubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meetin
April 09, 2021
From
GlobeNewswire News Releases
Tessera Therapeutics Strengthens Leadership Team to Advance ‘Gene Writing’ Platform & Accelerate Therapeutic Development
April 07, 2021
Tessera Therapeutics, a biotech company pioneering Gene Writing, announced today the appointment of David Davidson, M.D. as Chief Medical and Development Officer, Hari Pujar, Ph.D. as Chief Operating...
From
Business Wire News Releases
Thinking about buying stock in Arbutus Biopharma, Aemetis, FuboTV, Rubius Therapeutics, or Lithium Americas Corp?
April 01, 2021
InvestorsObserver issues critical PriceWatch Alerts for ABUS, AMTX, FUBO, RUBY, and LAC.
From
PR Newswire
Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion as President and Chief Commercial Officer
March 30, 2021
Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agriculture, nutrition and environmental...
From
PR Newswire
Rubius Therapeutics Prices Upsized Public Offering of Common Stock
March 16, 2021
From
GlobeNewswire News Releases
Rubius Therapeutics Announces Proposed Public Offering of Common Stock
March 15, 2021
From
GlobeNewswire News Releases
Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity
March 15, 2021
From
GlobeNewswire News Releases
Rubius Therapeutics Announces Webcast to Review Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors
March 12, 2021
From
GlobeNewswire News Releases
Rubius Therapeutics to Present Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meet
March 10, 2021
From
GlobeNewswire News Releases
Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target
February 25, 2021
Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it raised $123 million in Series B financing. The...
From
PR Newswire
Rubius Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
February 23, 2021
From
GlobeNewswire News Releases
Rubius Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
February 18, 2021
From
GlobeNewswire News Releases
Rubius Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results
February 09, 2021
From
GlobeNewswire News Releases
Rubius Therapeutics to Participate in Guggenheim Healthcare Talks | 2021 Oncology Days
February 03, 2021
From
GlobeNewswire News Releases
Rubius Therapeutics Provides Operational Update and Outlines 2021 Objectives at the 39th Annual J.P. Morgan Healthcare Conference
January 11, 2021
From
GlobeNewswire News Releases
Rubius Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
January 04, 2021
From
GlobeNewswire News Releases
Why Transdermal Drug Delivery Systems are Outweighing Advantages of Traditional Methods
December 15, 2020
Tags
Featured News
From
FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Why Transdermal Drug Delivery Systems are Outweighing Advantages of Traditional Methods
December 15, 2020
Financialnewsmedia.com News Commentary
From
PR Newswire
Rubius Therapeutics to Participate in Evercore ISI 3rd Annual HealthCONx Conference
November 30, 2020
From
GlobeNewswire News Releases
Rubius Therapeutics to Participate in Jefferies Virtual London Healthcare Conference
November 10, 2020
From
GlobeNewswire News Releases
Rubius Therapeutics Reports Third Quarter 2020 Financial Results and Strong Execution Across the Pipeline
November 09, 2020
From
GlobeNewswire News Releases
Rubius Therapeutics Presents Preclinical Data for Lead Red Cell Therapeutic™ Clinical Oncology Program, RTX-240, at the Society for Immunotherapy of Cancer’s Annual Meeting
November 09, 2020
RTX-240 Demonstrates Promotion of T Cell and Natural Killer Cell Activation and Expansion In Vitro and In Vivo
From
GlobeNewswire News Releases
Rubius Therapeutics Announces Dosing of First Patient with Relapsed/Refractory Acute Myeloid Leukemia in the Ongoing Phase 1/2 Clinical Trial of RTX-240
November 05, 2020
From
GlobeNewswire News Releases
Rubius Therapeutics to Announce Third Quarter 2020 Financial Results
October 29, 2020
From
GlobeNewswire News Releases
Rubius Therapeutics Presents Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, Demonstrating its Dual Mechanism of Action
October 28, 2020
RTX-321 Induces Antigen-Specific Stimulation Combined with Broad Stimulation of Innate and Adaptive Immune Responses
From
GlobeNewswire News Releases
Rubius Therapeutics Announces Preclinical Data Supporting its Lead Clinical Oncology Program, RTX-240, to be Presented at the Society for Immunotherapy of Cancer’s Annual Meeting
October 15, 2020
From
GlobeNewswire News Releases
Rubius Therapeutics to Participate in 7th Annual Jefferies Cell Therapy Summit
September 29, 2020
From
GlobeNewswire News Releases
Rubius Therapeutics Appoints Jose Carmona as Chief Financial Officer
September 28, 2020
From
GlobeNewswire News Releases
Rubius Therapeutics to Participate at Upcoming Investor Conferences
September 08, 2020
From
GlobeNewswire News Releases
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.